PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(12.59%)
USD 0.16
(12.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.04 Million CAD | 23.12% |
| 2023 | -3.95 Million CAD | 65.21% |
| 2022 | -3.95 Million CAD | 53.45% |
| 2021 | -2.42 Million CAD | -35679.0% |
| 2020 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.34 Million CAD | -18.73% |
| 2024 Q4 | -386.27 Thousand CAD | 13.84% |
| 2024 Q3 | -448.32 Thousand CAD | 51.01% |
| 2024 Q2 | -735.07 Thousand CAD | 31.99% |
| 2023 Q1 | -654.64 Thousand CAD | 76.31% |
| 2023 FY | - CAD | 65.21% |
| 2023 Q4 | -599.82 Thousand CAD | 27.61% |
| 2023 Q3 | -828.55 Thousand CAD | -217.86% |
| 2023 Q2 | 702.99 Thousand CAD | 207.38% |
| 2022 Q4 | -2.76 Million CAD | -426.34% |
| 2022 Q3 | 846.69 Thousand CAD | 143.72% |
| 2022 Q2 | -1.93 Million CAD | -1597.11% |
| 2022 Q1 | -114.11 Thousand CAD | 74.25% |
| 2022 FY | - CAD | 53.45% |
| 2021 Q4 | -443.15 Thousand CAD | 93.45% |
| 2021 FY | - CAD | -35679.0% |
| 2021 Q3 | -6.76 Million CAD | -480.28% |
| 2021 Q2 | -1.16 Million CAD | -242.44% |
| 2021 Q1 | -340.61 Thousand CAD | 0.0% |
| 2020 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | 0.641% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 14.199% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -33.219% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 82.479% |
| GB Sciences, Inc. | -1.41 Million USD | -114.339% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 903.33% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -24786.491% |
| Skye Bioscience, Inc. | -13.54 Million USD | 77.536% |
| Zenith Capital Corp. | -8.6 Million USD | 64.637% |
| Agentix Corp. | -1.37 Million USD | -121.859% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 21.65% |
| Biomind Labs Inc. | -1.03 Million USD | -194.173% |
| ContraFect Corporation | -64.99 Million USD | 95.318% |
| CSL Limited | 4.78 Billion USD | 100.064% |
| CytoDyn Inc. | -18.02 Million USD | 83.12% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 45361.288% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -381.237% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.5% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -728.757% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -98.13% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -224.817% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.236% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.255% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -104.608% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.716% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -15.085% |
| Mesoblast Limited | -62.38 Million USD | 95.122% |
| Marizyme, Inc. | -34.28 Million USD | 91.122% |
| Genus plc | 73.7 Million USD | 104.129% |
| Pharming Group N.V. | 9.87 Million USD | 130.813% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 65.306% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -117.103% |
| IMV Inc. | -35.52 Million USD | 91.433% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -30.964% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -487.471% |
| ONE Bio Corp. | 13.61 Million USD | 122.356% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.689% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 185.201% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -5.222% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 57.502% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -12073.476% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 80.823% |
| Alpha Cognition Inc. | -9.7 Million USD | 68.643% |
| Enzolytics Inc. | -2.12 Million USD | -43.418% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 98.591% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 350.071% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 134.374% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.776% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 48.669% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1172.577% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -24.399% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1628.948% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -58.434% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 53.969% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 32.761% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 18.766% |
| Helix BioMedix, Inc. | -1.04 Million USD | -190.866% |
| EV Biologics, Inc. | -1.26 Million USD | -140.178% |
| Q BioMed Inc. | -617.62 Thousand USD | -392.751% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -73.907% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 92.322% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 59.71% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -21.639% |
| HST Global, Inc. | -5303.00 USD | -57289.572% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -47.952% |
| Halberd Corporation | -74.27 Thousand USD | -3997.213% |
| Resverlogix Corp. | -11.74 Million USD | 74.081% |
| Cell Source, Inc. | -4.27 Million USD | 28.769% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -103.039% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | 50.212% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -17369.543% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -194.103% |
| Kadimastem Ltd | -2.62 Million USD | -15.965% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -701.688% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1580.602% |
| LadRx Corporation | 412.28 Thousand USD | 838.175% |
| Regen BioPharma, Inc. | 1.46 Million USD | 307.603% |
| Affymax, Inc. | -14.29 Million USD | 78.71% |
| Itoco Inc. | -1.86 Million USD | -62.835% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -172.703% |
| Mobile Lads Corp. | -2.24 Million USD | -35.794% |
| International Stem Cell Corporation | 202 Thousand USD | 1606.618% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 20.334% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3750.952% |
| Qrons Inc. | -40.08 Thousand USD | -7493.047% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -526.623% |
| SYBLEU INC | -141.57 Thousand USD | -2049.712% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 677.015% |
| Rebus Holdings, Inc. | -951 Thousand USD | -220.018% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -186.567% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5681.476% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -23.617% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.515% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6663.042% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -11.153% |
| Neutra Corp. | -181.24 Thousand USD | -1579.128% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 84.903% |
| PureTech Health plc | -11.62 Million USD | 73.825% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 84.902% |
| IXICO plc | -707 Thousand USD | -330.462% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 60.399% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.705% |
| CSL Limited | 4.73 Billion USD | 100.064% |
| Cellectis S.A. | -92.63 Million USD | 96.715% |